In this setting, the new incretin drugs such as glucagon-like peptide 1 receptor agonists (GLP-1 RA) have been used in HF patients with T2D, and interestingly, the risk of hospitalization for those patients was not increased. The gene discussed is GLP1R; the disease is hydrops fetalis.